CEACAM1 Activators
The category of CEACAM1 activators encompasses a diverse array of compounds capable of regulating the expression and activity of CEACAM1, a cell adhesion molecule pivotal to various cellular processes. These activators exhibit the ability to directly target CEACAM1 or indirectly influence its expression by impacting specific signaling pathways, providing a nuanced understanding of the intricate regulatory mechanisms governing this protein. One subset of CEACAM1 activators includes agonists for peroxisome proliferator-activated receptors (PPARs), such as Rosiglitazone, LY171883, and GW501516. These compounds indirectly activate CEACAM1 by binding to PPARγ and PPARα, respectively. PPARs are transcription factors that, upon activation, modulate gene expression, and their role in influencing CEACAM1 expression underscores the complex regulatory landscape of this cell adhesion molecule. Activation of PPARs leads to increased CEACAM1 expression, suggesting a regulatory role for PPARs in modulating CEACAM1.
Insulin represents another class of activators that indirectly impact CEACAM1 through the insulin receptor signaling pathway. Compounds like Metformin, a known AMP-activated protein kinase (AMPK) activator, and Roscovitine, a cyclin-dependent kinase inhibitor, showcase alternative pathways for CEACAM1 modulation. Metformin achieves CEACAM1 activation through the AMPK pathway, which is involved in cellular energy homeostasis. Roscovitine, on the other hand, indirectly influences CEACAM1 by modulating the cell cycle, further highlighting the multifaceted regulatory mechanisms influencing CEACAM1 expression. In conclusion, the diverse range of CEACAM1 activators presented here unveils avenues for comprehending and manipulating CEACAM1 expression. These compounds not only provide valuable tools for researchers but also offer insights into the intricate regulatory networks governing CEACAM1 and its role in various physiological and pathological processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone is a thiazolidinedione and an agonist of peroxisome proliferator-activated receptor gamma (PPARγ). Indirectly, it activates CEACAM1 by binding to PPARγ, a transcription factor known to regulate CEACAM1 expression. The activation of PPARγ by Rosiglitazone can lead to increased CEACAM1 expression, suggesting a regulatory role of PPARγ in CEACAM1 modulation. | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $82.00 $179.00 | 28 | |
GW501516 is a selective agonist of PPARδ. Indirectly, it activates CEACAM1 by binding to PPARδ, a member of the peroxisome proliferator-activated receptor family. The activation of PPARδ by GW501516 can lead to increased CEACAM1 expression, suggesting a regulatory role of PPARδ in CEACAM1 modulation. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin is a peptide hormone that activates the insulin receptor. Indirectly, it activates CEACAM1 by initiating the insulin receptor signaling pathway. The activation of this pathway by insulin can lead to increased CEACAM1 expression, suggesting a role for insulin in CEACAM1 modulation. | ||||||
Troglitazone | 97322-87-7 | sc-200904 sc-200904B sc-200904A | 5 mg 10 mg 25 mg | $110.00 $204.00 $435.00 | 9 | |
Troglitazone is a thiazolidinedione and an agonist of peroxisome proliferator-activated receptor gamma (PPARγ). Indirectly, it activates CEACAM1 by binding to PPARγ, a transcription factor known to regulate CEACAM1 expression. The activation of PPARγ by Troglitazone can lead to increased CEACAM1 expression, suggesting a regulatory role of PPARγ in CEACAM1 modulation. | ||||||
Clofibrate | 637-07-0 | sc-200721 | 1 g | $33.00 | ||
Clofibrate is a fibric acid derivative and a PPARα agonist. Indirectly, it activates CEACAM1 by binding to PPARα, a member of the peroxisome proliferator-activated receptor family. The activation of PPARα by Clofibrate can lead to increased CEACAM1 expression, suggesting a regulatory role of PPARα in CEACAM1 modulation. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Metformin is an antidiabetic drug that activates AMP-activated protein kinase (AMPK). Indirectly, it activates CEACAM1 by initiating the AMPK signaling pathway. The activation of this pathway by Metformin can lead to increased CEACAM1 expression, suggesting a role for AMPK in CEACAM1 modulation. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Fenofibrate is a fibric acid derivative and a PPARα agonist. Indirectly, it activates CEACAM1 by binding to PPARα, a member of the peroxisome proliferator-activated receptor family. The activation of PPARα by Fenofibrate can lead to increased CEACAM1 expression, suggesting a regulatory role of PPARα in CEACAM1 modulation. | ||||||
GW 0742 | 317318-84-6 | sc-203991 sc-203991A | 10 mg 50 mg | $194.00 $831.00 | 11 | |
GW0742 is a selective agonist of PPARδ. Indirectly, it activates CEACAM1 by binding to PPARδ, a member of the peroxisome proliferator-activated receptor family. The activation of PPARδ by GW0742 can lead to increased CEACAM1 expression, suggesting a regulatory role of PPARδ in CEACAM1 modulation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a selective cyclin-dependent kinase inhibitor. Indirectly, it activates CEACAM1 by inhibiting cyclin-dependent kinases, leading to cell cycle arrest. The modulation of the cell cycle by Roscovitine can impact CEACAM1 expression, suggesting a link between cell cycle regulation and CEACAM1 modulation. | ||||||